Profile data is unavailable for this security.
About the company
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is a China-based company primarily engaged in the business of pharmaceutical and health. The Company operates through four segments. The Great Southern Medicine segment is engaged in the research and development, manufacturing and sales of Chinese and Western patent medicines, chemical active pharmaceutical ingredients, biopharmaceuticals and natural medicines. The Great Health segment is engaged in the production, research and development and sales of beverages, food, health products and other products. The Great Commercial segment is engaged in the wholesale, retail and import and export of pharmaceutical products, medical devices, health products and other products. The Great Medical segment is engaged in the investment in medical services, traditional Chinese medicine health care, modern elderly care and medical device industries. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in HKD (TTM)87.69bn
- Net income in HKD3.38bn
- Incorporated1997
- Employees28.14k
- LocationGuangzhou Baiyunshan Pharmaceutical Holdings Co LtdNo. 45 Shamian North StreetLiwan DistrictGUANGZHOU 510130ChinaCHN
- Phone+86 2 066281218
- Fax+86 2 066281229
- Websitehttps://www.gybys.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sunshine Lake Pharma Co Ltd | 3.82bn | -447.80m | 24.19bn | 6.53k | -- | 54.74 | 20,257.62 | 6.34 | -0.7765 | -0.7765 | 6.62 | 0.7672 | -- | -- | -- | 582,679.50 | -- | -- | -- | -- | 73.62 | -- | -12.86 | -- | 0.7739 | -0.7591 | 0.5111 | -- | -37.06 | -- | -212.17 | -- | -- | -- |
| The United Laboratories Intl. Hldgs Ltd. | 15.95bn | 3.46bn | 24.90bn | 17.40k | 6.62 | 1.30 | 5.98 | 1.56 | 1.91 | 1.91 | 8.78 | 9.69 | 0.5397 | 2.89 | 5.97 | 938,145.00 | 11.71 | 9.37 | 17.46 | 14.54 | 47.24 | 44.33 | 21.70 | 15.06 | 1.60 | -- | 0.2472 | 26.01 | 0.1387 | 10.39 | -1.54 | 32.89 | 37.25 | 45.96 |
| Shanghai Henlius Biotech Inc | 6.56bn | 932.24m | 24.90bn | 3.54k | 41.95 | 10.15 | 17.65 | 3.80 | 1.72 | 1.72 | 12.06 | 7.09 | 0.5386 | 1.73 | 5.86 | 1,865,468.00 | 7.66 | -3.21 | 13.85 | -5.76 | 75.77 | 72.50 | 14.22 | -7.87 | 0.5046 | 10.47 | 0.5185 | -- | 6.11 | 128.98 | 50.26 | -- | 10.83 | -- |
| PegBio Co Ltd | -100.00bn | -100.00bn | 26.11bn | 58.00 | -- | 89.25 | -- | -- | -- | -- | -- | 0.7479 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.07 | -- | 0.2439 | -- | -- | -- | -1.49 | -- | -- | -- |
| Grand Pharmaceutical Group Ltd | 11.70bn | 2.08bn | 26.83bn | 12.44k | 12.72 | 1.54 | 10.35 | 2.29 | 0.5943 | 0.5943 | 3.35 | 4.90 | 0.4557 | 3.66 | 3.88 | 976,472.80 | 7.99 | 10.40 | 10.81 | 14.24 | 57.64 | 61.04 | 17.53 | 22.80 | 0.9872 | -- | 0.2107 | 29.12 | 10.59 | 12.06 | 31.30 | 16.49 | 0.7398 | 22.05 |
| China Resources Pharmaceutical Group Ltd | 295.11bn | 3.19bn | 29.34bn | 86.00k | 9.19 | 0.5192 | 2.25 | 0.0994 | 0.5083 | 0.5083 | 46.97 | 8.99 | 0.9434 | 5.57 | 2.41 | 4,059,329.00 | 2.86 | 3.14 | 10.28 | 11.78 | 15.81 | 15.59 | 3.03 | 3.02 | 1.12 | 11.26 | 0.4248 | 22.38 | 5.30 | 7.41 | -13.06 | 2.95 | 12.42 | 7.30 |
| Duality Biotherapeutics Inc | 2.45bn | -3.20bn | 29.48bn | 191.00 | -- | 8.74 | -- | 12.01 | -36.93 | -36.93 | 28.67 | 37.42 | -- | -- | -- | 14,438,690.00 | -- | -- | -- | -- | 37.13 | -- | -130.43 | -- | -- | -- | 0.0228 | -- | 8.66 | -- | -193.82 | -- | -- | -- |
| Simcere Pharmaceutical Group Ltd | 8.04bn | 995.43m | 31.88bn | 6.82k | 30.35 | 3.71 | 22.87 | 3.97 | 0.4047 | 0.4047 | 3.26 | 3.31 | 0.5845 | 2.20 | 2.81 | 1,220,719.00 | 7.24 | 8.74 | 9.93 | 12.42 | 81.00 | 78.53 | 12.39 | 15.60 | 1.57 | 4.72 | 0.1453 | 44.12 | 0.4148 | 5.67 | 2.57 | -6.09 | 8.48 | -- |
| Xuanzhu Biopharmaceutical Co Ltd | 36.14m | -629.22m | 33.93bn | 197.00 | -- | 35.47 | -- | 938.68 | -1.21 | -1.21 | 0.0698 | 1.85 | -- | -- | -- | -- | -- | -- | -- | -- | 41.02 | -- | -1,740.97 | -- | 1.10 | -- | 0.0013 | -- | 103,672.40 | -- | -85.13 | -- | -- | -- |
| China Medical System Holdings Ltd | 8.89bn | 1.87bn | 36.57bn | 6.10k | 19.41 | 1.90 | 16.95 | 4.11 | 0.7721 | 0.7721 | 3.68 | 7.89 | 0.4239 | 3.14 | 6.12 | 1,447,511.00 | 8.85 | 16.35 | 9.88 | 18.70 | 71.47 | 75.03 | 20.88 | 32.20 | 5.28 | -- | 0.0417 | 40.16 | -6.79 | 4.22 | -32.54 | -3.75 | 6.01 | -2.60 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 87.69bn | 3.38bn | 44.44bn | 28.14k | 9.35 | 0.7369 | -- | 0.5067 | 2.08 | 2.08 | 53.94 | 26.37 | 0.9548 | 5.79 | 4.33 | 3,116,519.00 | 3.83 | 5.33 | 7.36 | 10.95 | 16.23 | 18.07 | 4.01 | 5.28 | 1.31 | -- | 0.2871 | 28.87 | -0.692 | 2.92 | -30.09 | -2.32 | -14.01 | -- |
| 3SBio Inc | 10.26bn | 2.67bn | 59.49bn | 6.27k | 21.69 | 3.00 | 17.89 | 5.80 | 1.08 | 1.08 | 4.15 | 7.82 | 0.3799 | 1.54 | 6.97 | 1,840,106.00 | 10.46 | 7.95 | 15.09 | 10.32 | 85.37 | 83.73 | 27.54 | 22.68 | 2.12 | -- | 0.0899 | -- | 16.53 | 11.36 | 34.93 | 16.51 | 14.65 | -- |
Data as of Feb 13 2026. Currency figures normalised to Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's reporting currency: Hong Kong Dollar HKD
23.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| LSV Asset Managementas of 05 Jan 2026 | 11.02m | 5.01% |
| JPMorgan Asset Management (China) Co Ltd.as of 30 Jan 2026 | 10.94m | 4.97% |
| Norges Bank Investment Managementas of 27 Nov 2024 | 10.86m | 4.94% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 8.26m | 3.76% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 4.18m | 1.90% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 2.20m | 1.00% |
| Mellon Investments Corp.as of 09 Jan 2026 | 1.55m | 0.70% |
| KLP Kapitalforvaltning ASas of 30 Jan 2026 | 960.00k | 0.44% |
| SEI Investments Management Corp.as of 31 Dec 2025 | 577.76k | 0.26% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 406.00k | 0.19% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
